[1]World Health Organization(WHO). Global tuberculosis report 2013. Geneva: World Health Organization,2013.[2]Lu Y, Zheng M, Wang B, et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother, 2011, 55(11): 5185-5193.[3]Mariani F,Goletti D, Ciaramella A,et al. Macrophage response to Mycobacterium tuberculosis during HIV infection: relationships between macrophage activation and apoptosis. Curr Mol Med, 2001, 1(2): 209-216.[4]Barry VC, Belton JG, Conalty ML, et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature, 1957, 179(4568): 1013-1015.[5]Reddy VM, Nadadhur G, Daneluzzi D, et al. Antituberculosis activity of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother, 1996, 40(3): 633-636.[6]Jagannath C, Reddy MV, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med, 1995, 151(4): 1083-1086.[7]Reddy VM, O’Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother, 1999, 43(5): 615-623.[8]Xu J, Lu Y, Fu L, et al. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis, 2012,16(8): 1119-1125.[9]Grant SS, Kaufmann BB, Chand NS, et al. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci U S A, 2012, 109(30): 12147-12152.[10]Irwin SM, Gruppo V, Brooks E, et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother, 2014, 58(7): 4026-4034.[11]O’Neill AJ, Miller K, Oliva B, et al. Comparison of assays for detection of agents causing membrane damage in Staphylococcus aureus. J Antimicrob Chemother, 2004, 54(6): 1127-1129.[12]Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother, 2011, 55(12): 5485-5492.[13]Grosset JH, Tyagi S, Almeida DV, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med, 2013, 188(5): 608-612.[14]Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother, 2012, 56(6): 3114-3120.[15]Morrison NE, Marley GM. The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis, 1976, 44(1/2): 133-134.[16]Van Rensburg CE, Jooné GK, O’Sullivan JF, et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother,1992, 36(12): 2729-2735.[17]Yano T, Kassovska-Bratinova S, Teh JS, et al. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem, 2011, 286(12): 10276-10287.[18]De Bruyn EE, Steel HC, van Rensburg EJ, et al. The riminophenazines, clofazimine and B669, inhibit potassium transport in gram-positive bacteria by a lysophospholipid-dependent mechanism. J Antimicrob Chemother, 1996, 38(3): 349-362.[19]Steel HC, Matlola NM, Anderson R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother, 1999, 44(2): 209-216.[20]Matlola NM, Steel HC, Anderson R. Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. J Antimicrob Chemother, 2001, 47(2): 199-202.[21]Kagan VE. Tocopherol stabilizes membrane against phospholipase A, free fatty acids, and lysophospholipids. Ann N Y Acad Sci, 1989, 570: 121-135.[22]Anderson R, Zeis BM, Anderson IF. Clofazimine-mediated enhancement of reactive oxidant production by human phagocytes as a possible therapeutic mechanism. Dermatologica, 1988, 176(5): 234-242.[23]Cho SH, Warit S, Wan B, et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2007, 51(4): 1380-1385.[24]陆宇,王彬,赵伟杰,等.氯法齐明与其他抗结核药物联用对结核分枝杆菌的作用.中华结核和呼吸杂志,2010,33(9):675-678.[25]Adams LB, Sinha I, Franzblau SG, et al. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother, 1999, 43(7): 1638-1643.[26]张天民,杨树旺.氯苯吩嗪的药理学和临床应用.结核病临床与控制, 2002, 1(1): 39-42.[27]Schaad-Lanyi Z, Dieterle W, Dubois JP, et al. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis, 1987, 55(1): 9-15.[28]Yawalkar SJ, Vischer W. Lamprene (clofazimine) in leprosy. Basic information. Lepr Rev, 1979, 50(2): 135-144.[29]Desikan KV, Balakrishnan S. Tissue levels of clofamine in a case of leprosy. Lepr Rev, 1976, 47(2):107-113.[30]Manseld RE. Tissue concentrations of clofazimine(B663)in man. Am J Trop Med Hyg, 1974, 23(6): 1116-1119.[31]Garrelts JC. Clofazimine: a review of its use in leprosy and Mycohacterium avium complex infection. DICP, 1991, 25(5): 525-531.[32]Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs(Review). Int J Dermatol, 1985, 24(5): 280-285.[33]O’Connor R, O’Sullivan JF, O’Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab Rev,1995, 27(4): 591-614.[34]Gangadharam PR, Ashtekar D, O’Sullivan JF, et al. In vitro, in vivo, and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex. Tuber Lung Dis, 1992, 73(4): 192-199.[35]Venkatesan K, Deo N, Gupta UD. Tissue distribution and deposition of clofazimine in mice following oral administration with or without isoniazid. Arzneimittelforschung, 2007, 57(7): 472-474.[36]Horita Y, Doi N, et al. Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein. Antimicrob Agents Chmother, 2014, 58(6): 3168-3176.[37]Levy L. Pharmacologic studies of clofazimine. Am J Trop Med Hyg, 1974, 23(6): 1097-1109.[38]Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010, 182(5): 684-692.[39]Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet, 2004, 363(9407): 474-481.[40]Hawkins CC, Gold JW, Whimbey E, et al. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med, 1986, 105(2):184-188.[41]Xu HB, Jiang RH, Xiao HP. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect, 2011, 18(11): 1104-1110.[42]Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother, 2013, 68(2): 284-293.[43]Gopal M, Padayatchi N, Metcalfe JZ,et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis, 2013, 17(8): 1001-1007.[44]TB Alliance. Clofazimine. Tuberculosis (Edinb), 2008, 88(2): 96-99.[45]Van Rensburg CE, Anderson R, O’Sullivan JF. Riminophenazine compounds: pharmacology and anti-neoplastic potential. Crit Rev Oncol Hematol, 1997, 25(1): 55-67. |